Mit Delcath SYS Krebs örtlich bekämpfen
Seite 3 von 74 Neuester Beitrag: 24.04.21 23:43 | ||||
Eröffnet am: | 18.05.10 21:18 | von: Magnetfeldfr. | Anzahl Beiträge: | 2.846 |
Neuester Beitrag: | 24.04.21 23:43 | von: Katharinaqdlk. | Leser gesamt: | 403.732 |
Forum: | Hot-Stocks | Leser heute: | 116 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | | 4 | 5 | 6 | 7 | 8 | 9 | ... 74 > |
Aber was willste machen, wenn das Ding explodiert, dann halt wieder rein.
Getradet arg dämlich, Nobody is perfect.
Ich versuche es auszusitzen.
ich hab mir mal paar ins Depot gelegt , wenn die es packen , dann ohhh , und groß weiter fallen können die ja gar nicht mehr
Ich setze auf einen Erfolg des Medikamentes und eine Erstarkung der Firma auf dem Level wie vor einigen Jahren. Auch bin ich bereit eventuell 50% minus einzustecken. Denn bei einem Erfolg kann ich hier reich werden - Chance ist besser als die Lottoquote...
Würde mich über weitere Meinungen freuen.
so wie du schon schreibst , bei guten News sind schon höhere Kurse drinn , aber wie das bei Biotecs halt so ist , bis zum Ziel braucht man viel Nerven und Zeit . Mit den paar Stück die ich habe muss/ werd ich bis zum ganz großen Wurf warten ;-)
Bei der kleinen Firma kann der Kurs leicht gesteuert werden. Ich lasse mich nicht rausekeln und kaufe ggf. nach!
Kann dazu nichts finden. Oder ist bald was Positives spruchreif und die doofen Kleinanleger sollen noch schnell rausgeekelt werden?
Not surprised kei,after past week 10Q, Many have realized DCTH has legs and current tiny cap ($4m),far away from fair value.
a $4m Cap Co. among Johnson & Johnson ( $JNJ), Merck & Co., Inc ( $MRK), Pfizer Inc. ( $PFE), Novartis AG ( $AGS)
FDA approval +CE Mark too."The FDA has granted us six orphan drug designations, including three orphan designations for the use of the drug melphalan for the treatment of patients with mOM, HCC and ICC. Melphalan/HDS has not been approved for sale in the United States".
http://finance.yahoo.com/news/...er-cholangiocarcinoma-150500717.html
Folks are usually focusing U.S. market only but DCTH is a major P2/P3 World player for Duct Cancer and deep in EU market:
CHEMOSAT Available At Major Cancer Centers Throughout European Region:
1. CE Marked as Class IIb Medical Device with broad indication
2. >300 commercial procedures performed
3. Broad range of tumor types treated
4. Expansion into Turkey March 2016
5. National reimbursement established in Germany for 2016 after <3 years of commercial activity
2H2016:
• German ZE Reimbursement Level Defined
• P2 ICC Cohort Enrollment Completed
• EU Registry Data Readout #2
$32.2 million aggregate proceeds to fund clinical development programs, commercial activities & ongoing operations.
http://investorshub.advfn.com/boards/...msg.aspx?message_id=126632529
Remember AQXP? (from 1 to 30),if there any bio(s) that could be compare with, is DCTH. they both been trading way under cash,both had a solid balance sheet and upcoming catalysts. and I did same risk/reward calculation:
http://investorshub.advfn.com/boards/...msg.aspx?message_id=115900994
after past week 10Q, Many have realized DCTH has legs.approved medical device in Europe!.
Right now is good time to buy imo when not many are talking about it yet and analysts are just starting to cover. When Institutions start buying it will explode and will be to late imo
aus dem ihub vom 11.11.2016:
http://investorshub.advfn.com/boards/...msg.aspx?message_id=126498573
DCTH price book is now $24 per share.share price $1.8,not for long imo. very impressive earnings and updates. just Beats(10Q) trading 1/10 cash+ restricted, a major world player for duct cancer,( p2/p3( deep in EU market (CE MARK), FDA approval, very limited share count ( 2.1M O/S) and $24 per share book value. $3.5m cap vs 200m-300m co if succeeded or bought out. Never saw so impressive risk/ reward ratio.
Und ash111 ist einer von den richtig Guten im ihub. Der Junge hat schon bei AQXP und zuletzt bei SINO ein goldenes Näschen bewiesen !
http://investorshub.advfn.com/boards/...msg.aspx?message_id=126542413
$DCTH $2. Beats(10Q). DD: 2.1m O/S ($4m ap) vs $32m cash+ restricted+ net of current portion. will receive more $3m by Dec. Company did 1/16 split on June 2016(reasonable and positive due it was for a good reason to improve Equity. FDA approval+ Ce mark, deep in EU market.
If DCTH will succeed that's a $200m-$300m company while current cap is $4m (great risk/reward)
$DCTH Potential Market Size between $2-$8 Billion, similar companies from bio. field on same stage have value $400MM https://twitter.com/Donnaperan/status/797872942587711488
On Nov. 15, company will present at "British Society of Interventional Radiology" http://delcath.com/event/...sh-society-of-interventional-radiology-2/
10Q, Highlights:
1. DCTH beats. Revenues increased, Expenses decreased and net lose reduced by 70%. limited Cash burn rate too. company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.29) by $2.63.
Cash and cash equivalents $3.6m
Restricted cash $23.7m
Restricted cash, net of current portion $6.5m
2. the company will receive more $3 million Cash by December 31, 2016
3. Book Value increased to $24 per share
4. Expanded the FOCUS Phase 3 Trial in hepatic dominant ocular melanoma to include 10 new research centers in the U.S. and Europe.
5. In the United States, Melphalan/HDS is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The FDA has granted us six orphan drug designations, including three orphan designations for the use of the drug melphalan for the treatment of patients with mOM, HCC and ICC. Melphalan/HDS has not been approved for sale in the United States.
6. In Europe, the current version of our CHEMOSAT product is regulated as a Class IIb medical device and received its CE Mark in 2012. We are in an early phase of commercializing the CHEMOSAT system in select markets in the European Union where the prospect of securing adequate reimbursement for the procedure is strongest. In 2015 national reimbursement coverage for CHEMOSAT procedures was awarded in Germany, with coverage levels to be determined by German authorities in mid to late 2016.
7. Currently there are few effective treatment options for certain cancers in the liver. Traditional treatment options include surgery, chemotherapy, liver transplant, radiation therapy, interventional radiology techniques, and isolated hepatic perfusion. We believe that CHEMOSAT/Melphalan/HDS represents a potentially important advancement in regional therapy for primary liver cancer and certain other cancers metastatic to the liver. We believe that CHEMOSAT/Melphalan/HDS is uniquely positioned to treat the entire liver either as a stand-alone therapy or as a complement to other therapies.
Btw. Per this report DCTH is already a major World key player for Bile Duct Cancer (take a look, only a few big names here ): http://finance.yahoo.com/news/...er-cholangiocarcinoma-150500717.html
Bei fast 1 Mio gehandelten Stücken hätte ich allerdings etwas mehr erwartet...!?
Bitte um Beteiligung, danke!